BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 31229162)

  • 21. Cutaneous T-cell lymphomas. A review of the recent literature.
    Zackheim HS
    Arch Dermatol; 1981 May; 117(5):295-304. PubMed ID: 6971626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
    Wong HK; Mishra A; Hake T; Porcu P
    Br J Haematol; 2011 Oct; 155(2):150-66. PubMed ID: 21883142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current therapy concepts in cutaneous T-cell lymphomas].
    Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G
    Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mycosis fungoides and Sézary syndrome.
    Hwang ST; Janik JE; Jaffe ES; Wilson WH
    Lancet; 2008 Mar; 371(9616):945-57. PubMed ID: 18342689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy of cutaneous lymphoma--current practice and future developments.
    Dummer R; Kempf W; Hess Schmid M; Häffner A; Burg G
    Onkologie; 2003 Aug; 26(4):366-72. PubMed ID: 12972705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
    Sethi TK; Montanari F; Foss F; Reddy N
    Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.
    Hristov AC; Tejasvi T; A Wilcox R
    Am J Hematol; 2021 Oct; 96(10):1313-1328. PubMed ID: 34297414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
    Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
    Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Memorials and mandates for cutaneous lymphomas.
    Heald PW
    Arch Dermatol; 2003 Jul; 139(7):926-8. PubMed ID: 12873891
    [No Abstract]   [Full Text] [Related]  

  • 30. Local radiation for cutaneous T-cell lymphoma other than mycosis fungoides and Sézary syndrome.
    Shikama N
    Chin Clin Oncol; 2019 Feb; 8(1):8. PubMed ID: 30180750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.
    Isufi I; Seropian S; Gowda L; Wilson LD; Roberts K; Girardi M; Perreault S; Foss F
    Leuk Lymphoma; 2020 Dec; 61(12):2955-2961. PubMed ID: 32643494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new nail in the CTCL coffin.
    Lessin SR
    J Invest Dermatol; 2006 Nov; 126(11):2368-9. PubMed ID: 17041618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
    de Masson A; Beylot-Barry M; Ram-Wolff C; Mear JB; Dalle S; d'Incan M; Ingen-Housz-Oro S; Orvain C; Abraham J; Dereure O; Charbonnier A; Cornillon J; Longvert C; Barete S; Boulinguez S; Wierzbicka-Hainaut E; Aubin F; Rubio MT; Bernard M; Schmidt-Tanguy A; Houot R; Pham-Ledard A; Michonneau D; Brice P; Labussière-Wallet H; Bouaziz JD; Grange F; Moins-Teisserenc H; Jondeau K; Michel L; Mourah S; Battistella M; Daguindau E; Loschi M; Picard A; Franck N; Maillard N; Huynh A; Nguyen S; Marçais A; Chaby G; Ceballos P; Le Corre Y; Maury S; Bay JO; Adamski H; Bachy E; Forcade E; Socié G; Bagot M; Chevret S; Peffault de Latour R; ; ;
    Lancet; 2023 Jun; 401(10392):1941-1950. PubMed ID: 37105210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
    Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
    J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome.
    Golling P; Cozzio A; Dummer R; French L; Kempf W
    Leuk Lymphoma; 2008 Jun; 49(6):1094-103. PubMed ID: 18569636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Classification of primary cutaneous T-cell lymphomas.
    Willemze R; Beljaards RC; Meijer CJ
    Histopathology; 1994 May; 24(5):405-15. PubMed ID: 8088712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
    Whittaker SJ; Foss FM
    Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mycosis fungoides and Sézary syndrome - Review and outlook.
    Latzka J; Trautinger F
    J Dtsch Dermatol Ges; 2023 Apr; 21(4):386-391. PubMed ID: 36971307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario.
    Sanches JA; Cury-Martins J; Abreu RM; Miyashiro D; Pereira J
    An Bras Dermatol; 2021; 96(4):458-471. PubMed ID: 34053802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.